Novozymes Biopharma UK Limited. Patent applications |
Patent application number | Title | Published |
20140128326 | ALBUMIN VARIANTS - The present invention relates to variants of a parent albumin, the variants having altered plasma half-life compared with the parent albumin. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants. | 05-08-2014 |
20120322739 | Albumin Variants - The invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The invention also relates to fusion polypeptides and conjugates comprising said variant albumin. | 12-20-2012 |
20100222267 | RECOMBINANT TRANSFERRIN MUTANTS - The present invention provides a recombinant protein comprising the sequence of a transferrin mutant, wherein Ser415 is mutated to an amino acid which does not allow glycosylation at Asn413 and/or wherein Thr613 is mutated to an amino acid which does not allow glycosylation as Asn611. It also provides polynucleotides encoding the same and methods of making and using said recombinant protein. | 09-02-2010 |
20090197316 | PROCESS FOR PREPARING PARTICLES OF PROTEINACEOUS MATERIAL - Protein particles are prepared by causing or allowing protein molecules dispersed in a liquid medium at a concentration of 8 mg.mL-1 or greater to react in the presence of a zero-length crosslinker, so as to produce protein particles comprising protein molecules that are covalently bonded together. The protein particles may be produced with sizes in the sub-micron range with closely defined sizes and size distributions. The particles have applications in many fields, but are useful inter alia for the delivery of therapeutic agents and other agents, eg imaging contrast agents, to the body. | 08-06-2009 |
20090175893 | Albumin-Fused Anti-Angiogenesis Peptides - The invention relates to proteins comprising angiogenesis inhibiting peptides, such as endostatin peptides (including, but not limited to, fragments and variants thereof), which exhibit anti-retroviral activity, fused or conjugated to albumin (including, but not limited to fragments or variants of albumin). These fusion proteins are herein collectively referred to as “albumin fusion proteins of the invention.” These fusion proteins are herein collectively referred to as “albumin fusion proteins of the invention.” These fusion proteins exhibit extended shelf-life and/or extended or therapeutic activity in solution. The invention encompasses therapeutic albumin fusion proteins, compositions, pharmaceutical compositions, formulations and kits. The invention also encompasses nucleic acid molecules encoding the albumin fusion proteins of the invention, as well as vectors containing these nucleic acids, host cells transformed with these nucleic acids and vectors, and methods of making the albumin fusion proteins of the invention using these nucleic acids, vectors, and/or host cells. The invention also relates to compositions and methods for inhibiting proliferation of vascular endothelial cells and tumor angiogenesis induced cell fusion. The invention further relates to compositions and methods preventing growth of, or promoting regression of, primary tumors and metastases; and for treating cancer, diabetic retinopathy, progressive macular degeneration or rheumatoid arthritis. | 07-09-2009 |
20090171070 | Process for the Purification of Recombinant Albumin - A process is provided for the preparation of a highly pure recombinant albumin solution having a nickel ion content of less than 100 ng per gram of albumin. The process comprises subjecting a recombinant albumin to a series of chromatography, concentration, and diafiltration steps. | 07-02-2009 |
20080293638 | ALBUMIN-FUSED CILIARY NEUROTROPHIC FACTOR - The invention relates to a fusion protein comprising an albumin, or a fragment or a variant or a derivative thereof and at least one biologically active peptide which activates the ciliary neurotrophic factor (CNTF) receptor, or a fragment or variant or a derivative thereof. | 11-27-2008 |